Zacks: Analysts Expect Merck & Co., Inc. (NYSE:MRK) Will Announce Earnings of $1.14 Per Share

Analysts expect Merck & Co., Inc. (NYSE:MRK) to report earnings per share (EPS) of $1.14 for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Merck & Co., Inc.’s earnings, with the lowest EPS estimate coming in at $1.12 and the highest estimate coming in at $1.14. Merck & Co., Inc. posted earnings of $1.04 per share in the same quarter last year, which indicates a positive year-over-year growth rate of 9.6%. The company is expected to issue its next quarterly earnings results on Friday, February 7th.

According to Zacks, analysts expect that Merck & Co., Inc. will report full year earnings of $5.15 per share for the current year, with EPS estimates ranging from $5.12 to $5.17. For the next fiscal year, analysts anticipate that the company will report earnings of $5.49 per share, with EPS estimates ranging from $5.35 to $5.80. Zacks’ earnings per share averages are a mean average based on a survey of analysts that that provide coverage for Merck & Co., Inc..

Merck & Co., Inc. (NYSE:MRK) last issued its quarterly earnings data on Tuesday, October 29th. The company reported $1.51 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $1.24 by $0.27. Merck & Co., Inc. had a return on equity of 48.16% and a net margin of 20.26%. The business had revenue of $12.40 billion for the quarter, compared to the consensus estimate of $11.59 billion. During the same quarter last year, the business posted $1.19 EPS. The firm’s revenue was up 14.9% compared to the same quarter last year.

A number of research firms recently issued reports on MRK. Argus increased their target price on Merck & Co., Inc. to $105.00 and gave the stock a “buy” rating in a research note on Wednesday, August 7th. Morgan Stanley raised their target price on shares of Merck & Co., Inc. from $90.00 to $95.00 and gave the stock an “overweight” rating in a report on Wednesday, November 13th. Leerink Swann started coverage on shares of Merck & Co., Inc. in a research note on Thursday, August 15th. They issued an “outperform” rating and a $103.00 price target on the stock. Mizuho upped their price target on shares of Merck & Co., Inc. from $97.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, October 30th. Finally, Societe Generale set a $105.00 price target on shares of Merck & Co., Inc. and gave the company a “buy” rating in a report on Tuesday, September 3rd. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and thirteen have given a buy rating to the company’s stock. Merck & Co., Inc. presently has an average rating of “Buy” and an average target price of $95.47.

Shares of NYSE:MRK traded up $0.08 during trading on Friday, hitting $88.75. 7,562,733 shares of the company’s stock traded hands, compared to its average volume of 9,951,397. The company has a current ratio of 1.26, a quick ratio of 0.98 and a debt-to-equity ratio of 0.84. The company has a 50-day moving average price of $84.84 and a 200-day moving average price of $83.81. Merck & Co., Inc. has a 52 week low of $70.89 and a 52 week high of $88.73. The company has a market cap of $225.80 billion, a price-to-earnings ratio of 20.45, a price-to-earnings-growth ratio of 1.89 and a beta of 0.52.

The company also recently announced a quarterly dividend, which will be paid on Wednesday, January 8th. Shareholders of record on Monday, December 16th will be paid a $0.61 dividend. This is a boost from Merck & Co., Inc.’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, December 13th. This represents a $2.44 annualized dividend and a yield of 2.75%. Merck & Co., Inc.’s payout ratio is presently 50.69%.

Large investors have recently added to or reduced their stakes in the business. Webster Bank N. A. boosted its stake in shares of Merck & Co., Inc. by 7.3% during the 2nd quarter. Webster Bank N. A. now owns 29,607 shares of the company’s stock worth $2,483,000 after buying an additional 2,004 shares during the last quarter. Bogart Wealth LLC raised its holdings in Merck & Co., Inc. by 10.6% during the second quarter. Bogart Wealth LLC now owns 33,173 shares of the company’s stock worth $2,781,000 after acquiring an additional 3,192 shares in the last quarter. Northstar Group Inc. boosted its position in Merck & Co., Inc. by 1.1% during the second quarter. Northstar Group Inc. now owns 16,960 shares of the company’s stock valued at $1,422,000 after purchasing an additional 192 shares during the last quarter. AdvisorNet Financial Inc boosted its position in Merck & Co., Inc. by 0.8% during the second quarter. AdvisorNet Financial Inc now owns 44,029 shares of the company’s stock valued at $3,692,000 after purchasing an additional 350 shares during the last quarter. Finally, Forte Capital LLC ADV boosted its position in Merck & Co., Inc. by 6.1% during the second quarter. Forte Capital LLC ADV now owns 28,861 shares of the company’s stock valued at $2,420,000 after purchasing an additional 1,647 shares during the last quarter. 74.53% of the stock is owned by hedge funds and other institutional investors.

Merck & Co., Inc. Company Profile

Merck & Co, Inc provides healthcare solutions worldwide. It operates through four segments: Pharmaceutical, Animal Health, Healthcare Services, and Alliances. The company offers therapeutic and preventive agents to treat cardiovascular, type 2 diabetes, chronic hepatitis C virus, HIV-1 infection, intra-abdominal, fungal infection, insomnia, and inflammatory diseases.

Recommended Story: Insider Trading

Get a free copy of the Zacks research report on Merck & Co., Inc. (MRK)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.